Cargando…

Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa

INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashi, Murielle Longokolo, Mambimbi, Marcel Mbula, Situakibanza, Hippolyte Nani-Tuma, Ndona, Madone Mandina, Risassi, Jean-Robert Makulo, Ngongo, Nadine Mayasi, Bepouka, Ben, Ossam, Odio, Tshibola, Jean Mukaya, Tshienda, Frédéric Tshibasu, Kasongo, Eric Mukenge, Nzita, Mamy Ngole, Tuna, Lukiana, Lulebo, Aimée, Sonzi, Donatien Mangala, Lusunsi, Christian Kisoka, Longo-Mbenza, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460102/
https://www.ncbi.nlm.nih.gov/pubmed/37637394
http://dx.doi.org/10.11604/pamj.2023.45.63.39461
_version_ 1785097570406629376
author Mashi, Murielle Longokolo
Mambimbi, Marcel Mbula
Situakibanza, Hippolyte Nani-Tuma
Ndona, Madone Mandina
Risassi, Jean-Robert Makulo
Ngongo, Nadine Mayasi
Bepouka, Ben
Ossam, Odio
Tshibola, Jean Mukaya
Tshienda, Frédéric Tshibasu
Kasongo, Eric Mukenge
Nzita, Mamy Ngole
Tuna, Lukiana
Lulebo, Aimée
Sonzi, Donatien Mangala
Lusunsi, Christian Kisoka
Longo-Mbenza, Benjamin
author_facet Mashi, Murielle Longokolo
Mambimbi, Marcel Mbula
Situakibanza, Hippolyte Nani-Tuma
Ndona, Madone Mandina
Risassi, Jean-Robert Makulo
Ngongo, Nadine Mayasi
Bepouka, Ben
Ossam, Odio
Tshibola, Jean Mukaya
Tshienda, Frédéric Tshibasu
Kasongo, Eric Mukenge
Nzita, Mamy Ngole
Tuna, Lukiana
Lulebo, Aimée
Sonzi, Donatien Mangala
Lusunsi, Christian Kisoka
Longo-Mbenza, Benjamin
author_sort Mashi, Murielle Longokolo
collection PubMed
description INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compared to other antiretrovirals in predicting atherosclerosis in people living with HIV (PLHIV) and hospitalized in Kinshasa Hospital. METHODS: we conducted an interventional study of people living with HIV who had received antiretroviral therapy (ART) for at least 6 months and were treated in the structures of the network coordinated by the Catholic Church (BDOM-Bureau Diocésain des Oeuvres Médicales) and of the University Clinics of Kinshasa (CUK) between January 2017 and December 2021. Subclinical atherosclerosis was defined as Pulsed Pressure (PP) ≥60 mm Hg; Carotid Intima-Media Thickness (CIMT) > 0.8 mm; and Systolic Pressure Index (SPI) < 0.9. Logistic regression was used in the statistical analysis of associations. RESULTS: a total of 334 PLHIV were recruited, of whom 96.1% (n=321) were on ART and 13.9% (n=13) were ART naïve patients. The mean age of PLHIV was 51±12 years with a female predominance (70.4%; n=235); the independent determinants of subclinical atherosclerosis were marital status (aOR: 4. 95% CI 1.5-10.5; p<0.006), low socioeconomic level (aOR: 10.7, 95% CI 2.3-48.7 p<0.002), duration of HIV infection (aOR: 6.6, 95% CI 2.8-16; p<0.0001), duration of antiretroviral therapy ≥9 years (aOR: 0.3, 95% CI 0.2-0.7; p<0.005) and total cholesterol ratio/high-density lipoprotein-cholesterol (CT/HDL-c)(aOR: 2, 95% CI 1.1-3.6; p= 0.034). The mean values of traditional and emergent variables were significantly higher in the previous ART regimen without DTG than in the new regimen with DTG. However, dyslipidemia was detected during the new DTG-based regimen. CONCLUSION: dyslipidemia was common during the DTG-based regimen. Marital status, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9 years and the TC/HDL-c ratio were identified as determinants of subclinical atherosclerosis in PLHIV on ART hospitalized in the Kinshasa hospital.
format Online
Article
Text
id pubmed-10460102
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-104601022023-08-27 Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa Mashi, Murielle Longokolo Mambimbi, Marcel Mbula Situakibanza, Hippolyte Nani-Tuma Ndona, Madone Mandina Risassi, Jean-Robert Makulo Ngongo, Nadine Mayasi Bepouka, Ben Ossam, Odio Tshibola, Jean Mukaya Tshienda, Frédéric Tshibasu Kasongo, Eric Mukenge Nzita, Mamy Ngole Tuna, Lukiana Lulebo, Aimée Sonzi, Donatien Mangala Lusunsi, Christian Kisoka Longo-Mbenza, Benjamin Pan Afr Med J Research INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compared to other antiretrovirals in predicting atherosclerosis in people living with HIV (PLHIV) and hospitalized in Kinshasa Hospital. METHODS: we conducted an interventional study of people living with HIV who had received antiretroviral therapy (ART) for at least 6 months and were treated in the structures of the network coordinated by the Catholic Church (BDOM-Bureau Diocésain des Oeuvres Médicales) and of the University Clinics of Kinshasa (CUK) between January 2017 and December 2021. Subclinical atherosclerosis was defined as Pulsed Pressure (PP) ≥60 mm Hg; Carotid Intima-Media Thickness (CIMT) > 0.8 mm; and Systolic Pressure Index (SPI) < 0.9. Logistic regression was used in the statistical analysis of associations. RESULTS: a total of 334 PLHIV were recruited, of whom 96.1% (n=321) were on ART and 13.9% (n=13) were ART naïve patients. The mean age of PLHIV was 51±12 years with a female predominance (70.4%; n=235); the independent determinants of subclinical atherosclerosis were marital status (aOR: 4. 95% CI 1.5-10.5; p<0.006), low socioeconomic level (aOR: 10.7, 95% CI 2.3-48.7 p<0.002), duration of HIV infection (aOR: 6.6, 95% CI 2.8-16; p<0.0001), duration of antiretroviral therapy ≥9 years (aOR: 0.3, 95% CI 0.2-0.7; p<0.005) and total cholesterol ratio/high-density lipoprotein-cholesterol (CT/HDL-c)(aOR: 2, 95% CI 1.1-3.6; p= 0.034). The mean values of traditional and emergent variables were significantly higher in the previous ART regimen without DTG than in the new regimen with DTG. However, dyslipidemia was detected during the new DTG-based regimen. CONCLUSION: dyslipidemia was common during the DTG-based regimen. Marital status, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9 years and the TC/HDL-c ratio were identified as determinants of subclinical atherosclerosis in PLHIV on ART hospitalized in the Kinshasa hospital. The African Field Epidemiology Network 2023-05-26 /pmc/articles/PMC10460102/ /pubmed/37637394 http://dx.doi.org/10.11604/pamj.2023.45.63.39461 Text en Copyright: Murielle Longokolo Mashi et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mashi, Murielle Longokolo
Mambimbi, Marcel Mbula
Situakibanza, Hippolyte Nani-Tuma
Ndona, Madone Mandina
Risassi, Jean-Robert Makulo
Ngongo, Nadine Mayasi
Bepouka, Ben
Ossam, Odio
Tshibola, Jean Mukaya
Tshienda, Frédéric Tshibasu
Kasongo, Eric Mukenge
Nzita, Mamy Ngole
Tuna, Lukiana
Lulebo, Aimée
Sonzi, Donatien Mangala
Lusunsi, Christian Kisoka
Longo-Mbenza, Benjamin
Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa
title Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa
title_full Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa
title_fullStr Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa
title_full_unstemmed Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa
title_short Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa
title_sort étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de kinshasa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460102/
https://www.ncbi.nlm.nih.gov/pubmed/37637394
http://dx.doi.org/10.11604/pamj.2023.45.63.39461
work_keys_str_mv AT mashimuriellelongokolo etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT mambimbimarcelmbula etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT situakibanzahippolytenanituma etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT ndonamadonemandina etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT risassijeanrobertmakulo etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT ngongonadinemayasi etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT bepoukaben etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT ossamodio etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT tshibolajeanmukaya etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT tshiendafrederictshibasu etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT kasongoericmukenge etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT nzitamamyngole etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT tunalukiana etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT luleboaimee etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT sonzidonatienmangala etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT lusunsichristiankisoka etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa
AT longombenzabenjamin etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa